Compare Procter & Gamble Health with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs STRIDES PHARMA SCIENCE - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH STRIDES PHARMA SCIENCE PROCTER & GAMBLE HEALTH/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 50.9 15.1 337.9% View Chart
P/BV x 4.6 0.9 517.5% View Chart
Dividend Yield % 10.3 0.5 1,885.7%  

Financials

 PROCTER & GAMBLE HEALTH   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
STRIDES PHARMA SCIENCE
Mar-18
PROCTER & GAMBLE HEALTH/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs3,5491,147 309.4%   
Low Rs1,301642 202.7%   
Sales per share (Unadj.) Rs511.4317.2 161.2%  
Earnings per share (Unadj.) Rs61.37.8 781.3%  
Cash flow per share (Unadj.) Rs74.025.1 295.4%  
Dividends per share (Unadj.) Rs440.002.00 22,000.0%  
Dividend yield (eoy) %18.10.2 8,114.5%  
Book value per share (Unadj.) Rs927.8274.3 338.3%  
Shares outstanding (eoy) m16.6089.50 18.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.72.8 168.2%   
Avg P/E ratio x39.6114.0 34.7%  
P/CF ratio (eoy) x32.835.7 91.8%  
Price / Book Value ratio x2.63.3 80.1%  
Dividend payout %717.925.5 2,815.9%   
Avg Mkt Cap Rs m40,25780,058 50.3%   
No. of employees `0001.12.5 45.2%   
Total wages/salary Rs m1,3134,341 30.2%   
Avg. sales/employee Rs Th7,486.711,325.8 66.1%   
Avg. wages/employee Rs Th1,157.61,731.4 66.9%   
Avg. net profit/employee Rs Th897.2280.1 320.4%   
INCOME DATA
Net Sales Rs m8,49028,394 29.9%  
Other income Rs m244941 25.9%   
Total revenues Rs m8,73429,334 29.8%   
Gross profit Rs m1,4823,965 37.4%  
Depreciation Rs m2111,540 13.7%   
Interest Rs m01,962 0.0%   
Profit before tax Rs m1,5141,403 107.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m66-436 -15.1%   
Tax Rs m56397 578.1%   
Profit after tax Rs m1,017702 144.9%  
Gross profit margin %17.514.0 125.0%  
Effective tax rate %37.16.9 535.7%   
Net profit margin %12.02.5 484.6%  
BALANCE SHEET DATA
Current assets Rs m15,34324,836 61.8%   
Current liabilities Rs m1,96018,993 10.3%   
Net working cap to sales %157.620.6 766.0%  
Current ratio x7.81.3 598.6%  
Inventory Days Days4971 68.7%  
Debtors Days Days28113 25.1%  
Net fixed assets Rs m1,20934,289 3.5%   
Share capital Rs m166895 18.5%   
"Free" reserves Rs m15,23523,651 64.4%   
Net worth Rs m15,40124,546 62.7%   
Long term debt Rs m015,513 0.0%   
Total assets Rs m17,59565,437 26.9%  
Interest coverage xNM1.7-  
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.50.4 111.2%   
Return on assets %5.84.1 142.0%  
Return on equity %6.62.9 230.9%  
Return on capital %10.36.9 148.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,63615,697 10.4%   
Fx outflow Rs m4,368735 594.0%   
Net fx Rs m-2,73214,962 -18.3%   
CASH FLOW
From Operations Rs m-1,3041,871 -69.7%  
From Investments Rs m12,6975,826 217.9%  
From Financial Activity Rs m-301-10,157 3.0%  
Net Cashflow Rs m11,093-2,615 -424.2%  

Share Holding

Indian Promoters % 0.0 27.7 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 37.8 48.1%  
FIIs % 1.0 8.6 11.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 25.9 112.4%  
Shareholders   28,591 56,241 50.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   SHASUN PHARMA  WYETH LTD  ABBOTT INDIA  UNICHEM LAB  DR. REDDYS LAB  

Compare PROCTER & GAMBLE HEALTH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 642 Points; Automobile and Realty Stocks Plunge(Closing)

Indian share markets fell sharply today amid fears of rising crude oil prices and weakness in the rupee rattled investor sentiment.

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Sep 17, 2019 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 8-QTR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS